European report gets nasty about NICE and the QALY
This article was originally published in Scrip
Executive Summary
The QALY-based approach used by NICE, the health technology appraisal institute for England and Wales, is heavily flawed and should not be adopted by other European member states, warns a European Commission-sponsored project. The four main assumptions underpinning the QALY about how patients value additional life gain and different health states are invalid, according to the survey. "Everything it is based upon is wrong," said Ariel Beresniak, leader of the project which reported its results at a symposium in Brussels on 25 January.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.